文献速递临床试验与 GCP基础与转化研究

POINT试验更新方案:一项多中心随机对照试验研究术前肠内免疫营养对接受新辅助放化疗的食管癌患者的影响

Updated protocol of the POINT trial: a multicenter randomized controlled trial investigating effects of preoperative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy.
PubMed 文献 · Trials · 2025-10-10

POINT试验比较免疫营养补充剂与常规饮食在新辅助放化疗期间对可手术切除食管癌患者的作用,采用多中心、开放标签、随机对照设计,按2:1随机分配至营养治疗组或对照组,主要结局为术后营养和免疫相关并发症发生率。本次更新经上海交通大学医学院附属瑞金医院伦理委员会批准,参与者、干预和结局均有修订,预计最后1例患者于2025年底入组。

要点

  • POINT试验比较免疫增强肠内营养乳剂与常规饮食在新辅助放化疗食管癌患者中的效果。
  • 主要结局为术后营养和免疫相关并发症发生率,两组均接受新辅助放化疗联合微创食管切除术。
  • 更新包括增加排除标准、明确书面知情同意、延长新辅助放化疗至手术的窗口期及新增探索性终点。

核心结论

  • 这些修订与原始方案相比不影响试验的整体结局,预计最后1例患者于2025年底入组。

研究设计与样本

  • 正在进行的多中心、开放标签、随机对照试验,患者按2:1随机分配至营养治疗组或对照组。
  • 营养治疗组在新辅助放化疗期间接受免疫增强肠内营养乳剂,两组均接受新辅助放化疗联合放疗后行微创食管切除术。
  • 主要结局为术后营养和免疫相关并发症发生率。

主要发现

  • 参与者修订包括增加排除标准和明确书面知情同意。
  • 干预修订包括延长新辅助放化疗至手术的窗口期。
  • 结局修订包括新增两个探索性终点:微小残留病灶和新辅助放化疗前后肠道微生物群分布及代谢组学差异。
  • 已成立独立评估委员会进行持续安全性监测结局评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Preoperative Immunonutrition Therapy (POINT) trial compares immunonutrition supplements with a regular diet for surgically resectable esophageal patients during neoadjuvant chemoradiotherapy. The last patient is expected to be included by the end of 2025. The purpose of this update is to present all amendments to the POINT trial protocol as approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital. DESIGN: The initial protocol of the POINT trial has been previously published ( https://doi.org/10.1186/s12885-022-09721-y ). In this ongoing, multicenter, open-labeled, randomized controlled trial, patients are randomly assigned to nutrition therapy group or control group with a 2:1 ratio. Patients in the nutrition therapy group received immune-enhanced enteral nutritional emulsion during the neoadjuvant chemoradiotherapy. Both groups receive neoadjuvant chemoradiotherapy with concurrent radiotherapy followed by minimally invasive esophagectomy. The primary outcome is the rate of nutrition and immune-related complications after surgery. UPDATE: Amendments to the participants include the addition of exclusion criteria and the specification of written informed consent. Amendments to the intervention include an extended window period from neoadjuvant chemoradiotherapy to surgery. Amendments to the outcome include two additional exploratory endpoints, which are minimal residual disease and differences in the distribution of gut microbiota and metabolomics before and after neoadjuvant chemoradiotherapy. An independent assessment committee has been established to perform ongoing safety surveillance outcome evaluation. CONCLUSION: These amendments do not affect the overall outcomes of the trial compared to the original protocol. The last patient is expected to be included by the end of 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Cheng Y, Cao Y, Zhao S, et al. Updated protocol of the POINT trial: a multicenter randomized controlled trial investigating effects of preoperative enteral immunonutrition for esophageal cancer patients treated with neoadjuvant chemoradiotherapy. Trials. 2025. PMID: 41074192. doi:10.1186/s13063-025-09117-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。